Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer

[1]  Mark R. Marten,et al.  Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 , 2021, Autophagy.

[2]  J. Yap,et al.  Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers , 2019, Nature Medicine.

[3]  Laura E. Herring,et al.  KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. , 2018, Cancer cell.

[4]  Channing J Der,et al.  KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. , 2018, Cold Spring Harbor perspectives in medicine.

[5]  Robert E Denroche,et al.  Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. , 2018, Cancer discovery.

[6]  W. R. Bishop,et al.  Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. , 2018, JCI insight.

[7]  P. Zarrinkar,et al.  Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor , 2018, Cell.

[8]  Manish R. Patel,et al.  First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. , 2017, Cancer discovery.

[9]  Quan P. Ly,et al.  MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. , 2017, Cancer cell.

[10]  Richard A. Moore,et al.  Pyruvate Kinase Inhibits Proliferation during Postnatal Cerebellar Neurogenesis and Suppresses Medulloblastoma Formation. , 2017, Cancer research.

[11]  E. Petricoin,et al.  Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer , 2017, Clinical Cancer Research.

[12]  C. Der,et al.  Drugging RAS: Know the enemy , 2017, Science.

[13]  E. White,et al.  Autophagy, Metabolism, and Cancer , 2017, Cold Spring Harbor symposia on quantitative biology.

[14]  G. Hospers,et al.  Society of Surgical Oncology 70th Annual Cancer Symposium , 2017, Annals of Surgical Oncology.

[15]  Rebecca Rojansky,et al.  Elimination of paternal mitochondria in mouse embryos occurs through autophagic degradation dependent on PARKIN and MUL1 , 2016, eLife.

[16]  M. Wasik,et al.  13C MRS and LC–MS Flux Analysis of Tumor Intermediary Metabolism , 2016, Front. Oncol..

[17]  P. Stephens,et al.  Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2. , 2016, Cancer cell.

[18]  E. Sokol,et al.  AMPK promotes tolerance to Ras pathway inhibition by activating autophagy , 2016, Oncogene.

[19]  Shih-Hsun Chen,et al.  Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120. , 2016, Cancer discovery.

[20]  L. Scorrano,et al.  Mitochondrial Cristae: Where Beauty Meets Functionality. , 2016, Trends in biochemical sciences.

[21]  E. Petricoin,et al.  Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. , 2016, Cancer cell.

[22]  E. Petricoin,et al.  Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors , 2015, Oncotarget.

[23]  John M Asara,et al.  Small Molecule Inhibition of the Autophagy Kinase ULK1 and Identification of ULK1 Substrates. , 2015, Molecular cell.

[24]  L. Liotta,et al.  Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma , 2015, Annals of Surgical Oncology.

[25]  A. Kimmelman,et al.  Metabolic Dependencies in RAS-Driven Cancers , 2015, Clinical Cancer Research.

[26]  I. Ganley,et al.  Pharmacological Inhibition of ULK1 Kinase Blocks Mammalian Target of Rapamycin (mTOR)-dependent Autophagy* , 2015, The Journal of Biological Chemistry.

[27]  David F. Kashatus,et al.  Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth. , 2015, Molecular cell.

[28]  J. Chipuk,et al.  Mitochondrial division is requisite to RAS-induced transformation and targeted by oncogenic MAPK pathway inhibitors. , 2015, Molecular cell.

[29]  S. Fesik,et al.  Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.

[30]  John M. Asara,et al.  Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function , 2014, Nature.

[31]  J. Meyerhardt,et al.  Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. , 2014, The oncologist.

[32]  Gerald C. Chu,et al.  Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. , 2014, Cancer discovery.

[33]  D. Esposito,et al.  Dragging ras back in the ring. , 2014, Cancer cell.

[34]  M. Herlyn,et al.  Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. , 2014, The Journal of clinical investigation.

[35]  Channing J Der,et al.  KRAS: feeding pancreatic cancer proliferation. , 2014, Trends in biochemical sciences.

[36]  D. Bar-Sagi,et al.  Determining the macropinocytic index of cells through a quantitative image-based assay , 2014, Nature Protocols.

[37]  Eileen White,et al.  Exploiting the bad eating habits of Ras-driven cancers , 2013, Genes & development.

[38]  Christian M. Metallo,et al.  Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells , 2013, Nature.

[39]  Tomasz Arodz,et al.  Systems Analysis of the NCI-60 Cancer Cell Lines by Alignment of Protein Pathway Activation Modules with “-OMIC” Data Fields and Therapeutic Response Signatures , 2013, Molecular Cancer Research.

[40]  Shuxia Zhao,et al.  Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. , 2013, Cancer discovery.

[41]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[42]  M. Fukuda,et al.  Faculty Opinions recommendation of Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. , 2012 .

[43]  Jean-Charles Portais,et al.  IsoCor: correcting MS data in isotope labeling experiments , 2012, Bioinform..

[44]  Bond-Smith Giles,et al.  Only women with symptoms need to have their breast implants removed, says government , 2012 .

[45]  C. Galbán,et al.  Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. , 2012, The Journal of clinical investigation.

[46]  H. Ke,et al.  Beclin1 Controls the Levels of p53 by Regulating the Deubiquitination Activity of USP10 and USP13 , 2011, Cell.

[47]  R. Hruban,et al.  Tumor Engraftment in Nude Mice and Enrichment in Stroma- Related Gene Pathways Predict Poor Survival and Resistance to Gemcitabine in Patients with Pancreatic Cancer , 2011, Clinical Cancer Research.

[48]  Marc Liesa,et al.  Pancreatic cancers require autophagy for tumor growth. , 2011, Genes & development.

[49]  H. Coller,et al.  Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. , 2011, Genes & development.

[50]  Guo-Fang Zhang,et al.  Isotopomer enrichment assay for very short chain fatty acids and its metabolic applications. , 2011, Analytical biochemistry.

[51]  B. Viollet,et al.  AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1 , 2011, Nature Cell Biology.

[52]  Eileen White,et al.  Autophagy and Metabolism , 2010, Science.

[53]  J. Debnath,et al.  PLIC proteins or ubiquilins regulate autophagy‐dependent cell survival during nutrient starvation , 2009, EMBO reports.

[54]  A. Yamamoto,et al.  LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation , 2004, Journal of Cell Science.

[55]  E. Petricoin,et al.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.

[56]  H. Brunengraber,et al.  Correction of 13C mass isotopomer distributions for natural stable isotope abundance. , 1996, Journal of mass spectrometry : JMS.

[57]  P. Singh,et al.  Hypoxia-Induced Metabolomic Alterations in Pancreatic Cancer Cells. , 2018, Methods in molecular biology.

[58]  E. Petricoin,et al.  Reverse Phase Protein Microarrays. , 2017, Methods in molecular biology.

[59]  A. Giuliano,et al.  Guidelines for Guidelines: An Assessment of the American Society of Breast Surgeons Contralateral Prophylactic Mastectomy Consensus Statement , 2016, Annals of Surgical Oncology.

[60]  Lee,et al.  Editorial :Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). DOI: 10.1080/15548627.2015.1100356;WOS:000373595400001; 2-s2.0-85013763791&;PMID: 26799652 , 2016 .

[61]  N. Bardeesy,et al.  Pancreatic adenocarcinoma. , 2014, The New England journal of medicine.

[62]  M. Signore,et al.  Antibody validation by Western blotting. , 2012, Methods in molecular biology.

[63]  T. P. Neufeld,et al.  Guidelines for the use and interpretation of assays for monitoring autophage , 2012 .

[64]  P. M. Campbell,et al.  K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. , 2007, Cancer research.